

**Clinical Trials Summary for out of hours
Important Reference**

Acronym study title	Invigor011 Protocol number BO42843 IRAS ID 1003548
Study Details	A study to evaluate effects of Atezolizumab (anti-PD-L1-antibody) as an Adjuvant Therapy in patients with High-Risk Muscle-Invasive Bladder cancer
Principal Investigator PI Sub PI's	Professor Birtle Alison.birtle@lthtr.nhs.uk Telephone (secretary) 01772 524762
Research Nurse Team	Amanda Cook Amanda.cook@lthtr.nhs.uk Telephone 01772 524656 Catherine Walmsley Catherine.walmsley@lthtr.nhs.uk Telephone 01772 528475 Alternative daytime contact Stephanie Cornthwaite (Stephanie.cornthwaite@lthtr.nhs.uk) (01772 523581) Drug therapy
Drug therapy	Intravenous Atezolizumab or Placebo given on day 1 of 28 day cycle.
In the event that a patient calls this hotline for advise	Please treat as per clinical protocols and inform the clinical and research teams. Please liaise with the on-call Consultant or Registrar in the event of an emergency